Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | -13K |
| Operating Income | -80M | -70M | -56M | -42M | -23M |
| EBITDA | -80M | -70M | -56M | -39M | -21M |
| Net Income | -74M | -68M | -52M | -41M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.02
+4.80% today
1Y Change
-0.74%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rezolute, Inc. (RZLT) is a Healthcare stock with a market cap of $320.00M and listed on NASDAQ. The stock last traded around $5.02 and down 0.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +26.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.3%, free cash flow -20.4% with operating margin 0.0% and ROIC -69.3%. Stock Foundry combines RZLT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RZLT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RZLT Max Drawdown
-87.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RZLT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$20.9M
+49.1% YoY
Free Cash Flow
-$20.4M
+48.4% YoY
Revenue Growth
+0.0%
EPS Growth
+26.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | -13K |
| Operating Income | -80M | -70M | -56M | -42M | -23M |
| EBITDA | -80M | -70M | -56M | -39M | -21M |
| Net Income | -74M | -68M | -52M | -41M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 94M | 70M | 16M | 150M | 41M |
| Total Assets | 175M | 133M | 124M | 152M | 43M |
| Total Liabilities | 13M | 12M | 8M | 3M | 17M |
| Shareholder Equity | 162M | 121M | 116M | 149M | 26M |
| Total Debt | 2M | 2M | 2M | 188K | 14M |
| Net Debt | -92M | -68M | -14M | -150M | -27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
20M
+48.4% YoY
Capital Expenditures
0
Free Cash Flow
20M
+48.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-64.8%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.